Important It is possible that the main title of the report Creutzfeldt Jakob Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Subacute Spongiform Encephalopathy
Variant Creutzfeldt-Jakob Disease (V-CJD)
Creutzfeldt-Jakob disease (CJD) is an extremely rare degenerative brain disorder (i.e., spongiform encephalopathy) characterized by sudden development of rapidly progressive neurological and neuromuscular symptoms. With symptom onset, affected individuals may develop confusion, depression, behavioral changes, impaired vision, and/or impaired coordination. As the disease progresses, there may be rapidly progressive deterioration of cognitive processes and memory (dementia), resulting in confusion and disorientation, impairment of memory control, personality disintegration, agitation, restlessness, and other symptoms and findings. Affected individuals also develop neuromuscular abnormalities such as muscle weakness and loss of muscle mass (wasting); irregular, rapid, shock-like muscle spasms (myoclonus); and/or relatively slow, involuntary, continual writhing movements (athetosis), particularly of the arms and legs. Later stages of the disease may include further loss of physical and intellectual functions, a state of unconsciousness (coma), and increased susceptibility to repeated infections of the respiratory tract (e.g., pneumonia). In many affected individuals, life-threatening complications may develop less than a year after the disorder becomes apparent.
In approximately 90 percent of cases, CJD appears to occur randomly for no apparent reason (sporadically). About 10 percent of affected individuals may have a hereditary predisposition for the disorder. Reports in the medical literature suggest that familial cases of CJD are consistent with an autosomal dominant mode of inheritance. In addition, in some extremely rare cases, CJD may take an infectious form. The disorder is thought to result from changes (mutations) in the gene that regulates the production of the human prion protein or direct contamination (transmission) with abnormal prion protein in infected brain tissue.
A variant form of CJD (V-CJD) has been reported in the United Kingdom that affects younger people (median age at onset: 28 years) than does classic CJD. In 1996, experts suggested the possibility that this variant might be associated with consumption of beef from cows with a related infectious brain disorder known as Bovine Spongiform Encephalopathy (BSE) or "Mad Cow Disease." BSE was first identified in the UK in 1986 and the number of reported cases grew rapidly, peaking in the winter of 1992-93 when almost 1,000 new cases were reported each week. Later, BSE also began to appear in some other European countries. Scientific research and debate continue concerning the potential link between BSE and V-CJD. In addition, coordinated national and international efforts are in place concerning the prevention, study, and surveillance of BSE and CJD. In early December 2000, European Union agriculture ministers agreed upon new measures to combat the spread of mad cow disease, including incinerating any cow over 30 months of age that had not tested negative for BSE. (BSE is thought to become detectable and infectious when cattle are approximately 30 months old.)
Alzheimer's Association 225 N. Michigan Avenue 17th Floor Chicago, IL 60601 USA Tel: (312)335-8700 Fax: (866)699-1246 Tel: (800)272-3900 TDD: (312)335-5886 Email: firstname.lastname@example.org Internet: http://www.alz.org
Centers for Disease Control and Prevention 1600 Clifton Road NE Atlanta, GA 30333 Tel: (404)639-3534 Tel: (800)232-4636 TDD: (888)232-6348 Email: email@example.com Internet: http://www.cdc.gov/
National Hospice and Palliative Care Organization 1731 King Street, Suite 100 Alexandria, VA 22314 USA Tel: (703)837-1500 Fax: (703)837-1233 Tel: (800)658-8898 Email: firstname.lastname@example.org Internet: http://www.nhpco.org
NIH/National Institute of Allergy and Infectious Diseases Office of Communications and Government Relations 6610 Rockledge Drive, MSC 6612 Bethesda, MD 20892-6612 Tel: (301)496-5717 Fax: (301)402-3573 Tel: (866)284-4107 TDD: (800)877-8339 Email: email@example.com Internet: http://www.niaid.nih.gov/
NIH/National Institute of Neurological Disorders and Stroke P.O. Box 5801 Bethesda, MD 20824 Tel: (301)496-5751 Fax: (301)402-2186 Tel: (800)352-9424 TDD: (301)468-5981 Internet: http://www.ninds.nih.gov/
World Health Organization (WHO) Avenue Appia 20 Geneva 27, 1211 Switzerland Tel: 41227912111 Fax: 41227913111 Internet: http://www.who.int/en/
Creutzfeldt-Jakob Disease Foundation, Inc. PO Box 5312 Akron, OH 44334 USA Tel: (330)665-5590 Fax: (330)668-2474 Tel: (800)659-1991 Email: firstname.lastname@example.org Internet: http://www.cjdfoundation.org
CJD Voice Internet: http://www.cjdvoice.org
CJD Aware! 2527 South Carrollton Avenue New Orleans, LA 70118-3013 USA Tel: (504)861-4627 Email: email@example.com Internet: http://www.cjdaware.com
National Prion Disease Pathology Surveillance Center Institute of Pathology Case Western Reserve University 2085 Adelbert Road, Room 418 Cleveland, OH 44106-4907 USA Tel: (216)368-0587 Fax: (216)368-4090 Email: firstname.lastname@example.org Internet: http://www.cjdsurveillance.com
Genetic and Rare Diseases (GARD) Information Center PO Box 8126 Gaithersburg, MD 20898-8126 Tel: (301)251-4925 Fax: (301)251-4911 Tel: (888)205-2311 TDD: (888)205-3223 Internet: http://rarediseases.info.nih.gov/GARD/
UCSF Memory and Aging Center 350 Parnassus Avenue Suite 905 San Francisco, CA 94117 Tel: (415)476-6880 Fax: (415)476-4800 Email: email@example.com Internet: http://www.memory.ucsf.edu
C-Mac Informational Services, Inc. 120 Clinton Lane Cookeville, TN 38501-8946 Tel: (931)268-1201 Email: firstname.lastname@example.org Internet: http://www.caregivernews.org
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders (NORD). A copy of the complete report can be downloaded free from the NORD website for registered users. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational therapies (if available), and references from medical literature. For a full-text version of this topic, go to www.rarediseases.org and click on Rare Disease Database under "Rare Disease Information".
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 4/7/2009 Copyright 1984, 1985, 1987, 1988, 1990, 1991, 1992, 1994, 1996, 1997, 1998, 1999, 2000, 2001, 2003, 2007, 2009 National Organization for Rare Disorders, Inc.
How this information was developed to help you make better health decisions.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.